GlassScriptPhysician profile
Charles Rouse
NPI 1528383536
$28,272.86
in general payments reported to CMS, 2019-2025
24 companies · $9,694 in 2025
The $9,694 reported for 2025 was more than what 80% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $363 · 2021: $506 · 2022: $753 · 2023: $1,284 · 2024: $14K · 2025: $9,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $4,145 · Food and Beverage: $3,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,925.00 |
| Travel and Lodging | $4,145.39 |
| Food and Beverage | $3,391.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $10,856.64 | 2019-2025 | Carto 3, Octaray Mapping Catheter, Qdot Micro Catheter |
| Medical Device Business Services, INC. | $9,825.00 | 2024-2025 | Carto 3 |
| Abbott Laboratories | $5,210.10 | 2019-2025 | Aveir, Cardiomems, Amplatzer Amulet |
| Boston Scientific Corporation | $492.44 | 2019-2023 | Watchman Flx, Watchman, Watchman Access System |
| Biotronik INC. | $459.71 | 2019-2022 | |
| Amgen INC. | $186.51 | 2019-2024 | Repatha |
| Medtronic, INC. | $164.74 | 2021-2023 | Flexcath Advance |
| Genentech USA, INC. | $139.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $116.98 | 2019-2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $115.90 | 2019-2024 | Evkeeza |
| Janssen Pharmaceuticals, INC | $98.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.49 | 2020-2025 | |
| Amarin Pharma, INC. | $66.43 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.98 | 2019-2025 | Lifevest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $58.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.64 | 2023-2025 | Wainua |
| Medtronic Vascular, INC. | $54.56 | 2019 | |
| Pfizer INC. | $44.84 | 2025 | |
| Sanofi-Aventis U.S. LLC | $38.32 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $37.03 | 2023 | Optimizer |
| Cardiva Medical, INC. | $28.53 | 2025 | Cardiva Catalyst II Vcs |
| Alnylam Pharmaceuticals INC. | $20.36 | 2025 | Amvuttra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.